Drug Trial Radar · NCT06110923
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Nov 13, 2023
Primary completion
May 10, 2024
Study completion Mar 25, 2025
Sponsor
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
Conditions
- Benign Prostate Hypertrophy(BPH)
Interventions
CKD-846Drug
once administration of Investigational Product
D091Drug
once administration of Investigational Product per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of CKD-846Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)
- Concentration of D091Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.